Celcuity Inc.

Equities

CELC

US15102K1007

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
21.6 USD +18.94% Intraday chart for Celcuity Inc. +22.59% +48.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating MT
Needham Adjusts Price Target on Celcuity to $24 From $23, Keeps Buy Rating MT
Transcript : Celcuity Inc., Q4 2023 Earnings Call, Mar 27, 2024
Celcuity Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Celcuity Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer CI
Stifel Initiates Celcuity With Buy Rating, Price Target is $40 MT
Celcuity Appoints Eldon Mayer as Chief Commercial Officer CI
HC Wainwright Starts Coverage on Celcuity with Buy Rating, $27 Price Target MT
Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium CI
Transcript : Celcuity Inc., Q3 2023 Earnings Call, Nov 13, 2023
Celcuity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms DJ
Celcuity Inc. announced that it has received $49.999999 million in funding CI
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Sliding Wednesday Afternoon MT
Celcuity Launches $50 Million Private Placement; Shares Rise MT
Celcuity Inc. announced that it expects to receive $50 million in funding CI
Transcript : Celcuity Inc. - Shareholder/Analyst Call
Celcuity Inc.(NasdaqCM:CELC) added to S&P Global BMI Index CI
Celcuity to Proceed With Phase 1b/2 Trial of Gedatolisib Plus Nubeqa, Signs Supply Agreement With Bayer MT
Celcuity Inc. Announces Plan to Conduct Phase 1B/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer CI
Celcuity Inc. Enters into Clinical Trial Collaboration and Supply Agreement with Bayer AG to Provide Nubeqa (Darolutamide) for Phase 1B/2 Clinical Trial CI
Transcript : Celcuity Inc., Q2 2023 Earnings Call, Aug 10, 2023
Celcuity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart Celcuity Inc.
More charts
Celcuity, Inc. is a clinical-stage biotechnology company focused on the development of targeted therapies for treatment of multiple solid tumor indications. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients to benefit from targeted therapies. Its lead therapeutic candidate is gedatolisib, a potent, small molecule dual inhibitor that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Its mechanism of action and pharmacokinetic properties are highly differentiated from other investigational therapies that target PI3K or mTOR alone or together. Its initial clinical development program for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), HER2-negative, advanced or metastatic breast cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
21.6 USD
Average target price
28.6 USD
Spread / Average Target
+32.41%
Consensus
  1. Stock
  2. Equities
  3. Stock Celcuity Inc. - Nasdaq
  4. News Celcuity Inc.
  5. MT Newswires After Hours Watch List: CELC, FUBO, PRVB